(NASDAQ: IRD) Opus Genetics's forecast annual revenue growth rate of 15.49% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.28%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.61%.
Opus Genetics's revenue in 2025 is $14,633,000.On average, 9 Wall Street analysts forecast IRD's revenue for 2025 to be $947,430,290, with the lowest IRD revenue forecast at $763,709,639, and the highest IRD revenue forecast at $1,105,910,039. On average, 9 Wall Street analysts forecast IRD's revenue for 2026 to be $1,296,113,325, with the lowest IRD revenue forecast at $675,849,238, and the highest IRD revenue forecast at $2,172,372,552.
In 2027, IRD is forecast to generate $1,536,315,662 in revenue, with the lowest revenue forecast at $675,849,238 and the highest revenue forecast at $3,106,975,499.